Key result
Prior COVID-19 in HFrEF is linked to ~30% more NYHA III-IV symptoms and reduced LVEF.
Why the study?
COVID-19 affects the cardiovascular system and may worsen clinical status and reduce contractility in chronic heart failure, but its impact on functional class and echocardiographic parameters in HFrEF required evaluation.
Does a history of COVID-19 worsen functional class and echocardiographic parameters in patients with HFrEF?
Does a history of COVID-19 worsen functional class and echocardiographic parameters in patients with HFrEF?
A history of COVID-19 in patients with HFrEF is associated with worse functional status and reduced left and right ventricular systolic function.
May warrant closer monitoring in HFrEF with prior COVID-19; leaves open causality and need for prospective trials.
Introduction Coronavirus infection (COVID-19) significantly affects the cardiovascular system, leading to myocardial injury, inflammation and endothelial dysfunction. In patients with chronic heart failure (CHF) these changes may worsen clinical status and reduce myocardial contractility. Purpose To evaluate the impact of previous COVID-19 on functional class and echocardiographic parameters in patients with heart failure with reduced ejection fraction (HFrEF). Methods We conducted a retrospective analysis of medical records from 348 patients diagnosed with CHF (left ventricular ejection fraction (LVEF) ≤40%), who were hospitalised in a specialised cardiology centre, between 2020 and 2022. Patients were divided into two groups: those with a history of COVID-19 (PCR-positive, SARS-CoV-2 IgG >10 BAU/mL, n=174) and those without (PCR-negative, SARS-CoV-2 IgG ≤10 BAU/mL, n=174). We assessed the New York Heart Association (NYHA) functional class, LVEF, tissue Doppler imaging of the free right ventricular wall (S'RV) and tricuspid annular plane systolic excursion (TAPSE). For statistical analysis we used the non-parametric Mann-Whitney U test and Pearson’s χ² test for categorical variables. Results First, we assessed confounding factors between the groups, including age (p = 0.785), CHF duration (p = 0.315) and adherence to therapy (p = 0.072). Since the groups were comparable, we focused on functional and echocardiographic characteristics. We found that the proportion of patients with NYHA functional class III–IV was 1.3 times higher in the CHF with COVID-19 group, while those with class I–II were 2.5 times more common in the CHF without COVID-19 group (p = 0.004). LVEF was statistically significantly higher in patients without COVID-19 (29% vs 26.5%, p = 0.018). The S'RV was also higher in the non-COVID group (9.2 cm/sec vs 8.0 cm/sec, p < 0.001). Similarly, TAPSE differed statistically significant between the CHF without and with COVID-19 groups (1.8 cm vs 1.4 cm, respectively, p < 0.001). Conclusions A history of COVID-19 is associated with a worsening of NYHA functional class, decreased LVEF, S'RV, and TAPSE in patients with HFrEF. These findings highlight the need to consider previous COVID-19 infection when managing CHF patients and underscore the necessity for further research.
No takes yet. Share an insight, caveat, or question.
Absamatova et al. (2025) studied this question. Previous COVID-19 in HFrEF patients is linked to 1.3x higher NYHA III-IV, lower LVEF (26.5% vs 29%), S'RV (8.0 vs 9.2 cm/sec), and TAPSE (1.4 vs 1.8 cm).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: